Leo Cancer Care has raised $65 million in a financing round to scale manufacturing and accelerate commercial deployment of its upright integrated proton therapy, photon therapy, and imaging system.
The system is built around imaging and treating patients in an upright position rather than the conventional supine position used with gantry-based systems, the company said. The proton therapy component uses a fixed radiation beam with a rotating seated patient, which the firm said allows for a smaller treatment room that can fit within existing radiotherapy vaults. Stanford Medicine used the system to treat a pediatric brain tumor patient on June 4, Leo Cancer Care said.
The round was led by Yu Galaxy, with new investor Eventide Asset Management and the company's existing investors also participating, the company noted.
